E3 ubiquitin-protein ligase that functions in the antephase checkpoint by actively delaying passage into mitosis in response to microtubule poisons. Acts in early prophase before chromosome condensation, when the centrosome move apart from each other along the periphery of the nucleus. Probably involved in signaling the presence of mitotic stress caused by microtubule poisons by mediating the 'Lys-48'-linked ubiquitination of target proteins, leading to their degradation by the proteasome. Promotes the ubiquitination and subsequent degradation of AURKA and PLK1. Probably acts as a tumor suppressor, possibly by mediating the polyubiquitination of HDAC1, leading to its degradation. May also promote the formation of 'Lys-63'-linked polyubiquitin chains and functions with the specific ubiquitin-conjugating UBC13-MMS2 (UBE2N-UBE2V2) heterodimer. Substrates that are polyubiquitinated at 'Lys-63' are usually not targeted for degradation, but are rather involved in signaling cellular stress. Interacts with HDAC1 and HDAC2. Interacts with PML (with sumoylated form of PML). Ubiquitous. Belongs to the CHFR family. 5 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Protein type: EC 6.3.2.-; Ubiquitin ligase; EC 220.127.116.11; Ligase; Ubiquitin conjugating system
Molecular Function: ligase activity; nucleotide binding; protein binding; ubiquitin-protein ligase activity; zinc ion binding
Biological Process: cell division; mitosis; mitotic cell cycle checkpoint; modification-dependent protein catabolic process; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; positive regulation of protein ubiquitination; protein destabilization; protein polyubiquitination; ubiquitin-dependent protein catabolic process
Alt. Names/Synonyms: checkpoint with forkhead and ring finger domains; Checkpoint with forkhead and RING finger domains protein; CHFR; E3 ubiquitin-protein ligase CHFR; FLJ10796; FLJ33629; RING finger protein 196; RNF116; RNF196
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.